Loading stock data…
STAAR Surgical Company (STAA)
$23.38-0.81 (-3.35%)
Market ClosedLast close Jul 24
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
STAAR Surgical Company in the Healthcare sector is trading at $23.38 with a market capitalization of $1.4B. Wall Street consensus targets $30.00 (8 analysts), implying a +28.3% move over the next 12 months. The stock is currently 35% below its 52-week high of $35.87, remaining 4.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +28.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $93.52M↑ | $57.80M↓ | $94.73M↑ | $44.32M↑ | $42.59M |
| Gross Profit | $68.86M↑ | $43.74M↓ | $77.88M↑ | $32.80M↑ | $28.00M |
| Operating Income | $17.40M↑ | -$10.94M↓ | $24.44M↑ | -$24.72M↑ | -$34.74M |
| Net Income | $5.21M↑ | -$18.31M↓ | $8.88M↑ | -$16.81M↑ | -$54.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.97%
Volume
Today's trading volume
477,820
Recent News
STAAR Surgical (STAA) Is Down 16.5% After Doubling Q2 2026 Sales Guidance – Has The Bull Case Changed?
STAAR Surgical Company recently issued preliminary guidance indicating net sales for the second quarter of 2026 are expected to exceed US$90,000,000, compared with US$44,300,000 in the same quarter of 2025. This more than doubling of anticipated quarterly revenue suggests a step-change in sales momentum that could influence how investors assess the company’s operational progress. We’ll now examine how this sharp upgrade to second-quarter revenue expectations may influence STAAR Surgical’s...
STAAR Surgical, Globus Medical, Integer Holdings, and Enovis Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after a key industry player warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. The concern was raised by Intuitive Surgical, which noted that shifting insurance coverage could dampen the number of medical procedures performed in the United States. This news has investors worried about near-term demand, not just for one company, but for the entire industry reliant on a steady volu
3 Unprofitable Stocks with Questionable Fundamentals
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Staar Surgical China Turnaround Continues to Boost Confidence, Wedbush Says
Staar Surgical's (STAA) recent quarterly results continue to boost confidence that the medical techn
3 Reasons to Avoid STAA and 1 Stock to Buy Instead
STAAR Surgical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 7.7%. The stock now trades at $27.81, marking a 16.2% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.